Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?

Digestive Diseases and Sciences

Volumn 60, Issue 3, 2015, Pages 664-671

  Bresalier, Robert S ^a   Kopetz, Scott ^a   Brenner, Dean E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Blood based markers; Colon cancer; Fecal occult blood testing; Screening

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; COLORECTAL NEOPLASMS; HUMAN; IMMUNOLOGICAL PROCEDURES; MASS SCREENING; OCCULT BLOOD; PROCEDURES;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOLOGIC TESTS; MASS SCREENING; OCCULT BLOOD;

EID: 84928347151     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3575-2     Document Type: Review

References (66)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;62:9–29.
2. American Cancer Society. Colorectal cancer facts and figures 2011–2013. Atlanta: American Cancer Society; 2011.
3. Siegel R, Ward E, Brawley O, Jemal A, Cancer statistics. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–236.
4. Levin B, Lieberman DA, McFarland B, et al. American Cancer Society Colorectal Cancer Advisory Group, US Multi-Society Task Force, American College of Radiology Colon Cancer Committee. Gastroenterology. 2008;5:1570–1595.
5. Centers for Disease C, Prevention. Vital signs: colorectal cancer screening test use—United States, 2012. MMWR. 2013;62:881–888.
6. Surveillance E, End Results Program. SEER Stat Fact Sheets: Colon and Rectum Cancer: Centers for Disease Control; 2014. http://seer.cancer.gov/statfacts/html/colorect.html.
7. Green BB, Wang CY, Anderson ML, et al. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med. 2013;158:301–311. PMCID: 3953144.
8. National Center for Health Statistics. National Health Interview Survey (NHIS) public use data release: NHIS survey description. Hyattsville, MD: US Department of Health and Human Services, CDC, national Center for Health Statistics 2011; 2010. ftp://ftp.cdc.gov/pub/health_statistics/nchs/dataset_documentation/nhis/2010/srv.
9. Hoang TV, Gor BJ, Liang J, Esparza A, et al. Asian American Health Needs Assessment, 2006 community report. Houston, TX: The University of Texas MD Anderson Cancer Center; 2006.
10. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.
11. Degnan N, Patnick J, Von Karsa L, eds. International Agency for Research on Cancer. European Guidelines for Quality Assurance in Colorectal cancer Screening and Diagnosis. 1st edn. Belgium: European Union; 2010.
12. Cancer Care Ontario. Colon cancer check 2010 program report. Cancer Care Ontario, Toronto Canada; 2012. www.cancercare.on.ca/coloscreening.
13. Imperiale T, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297.
14. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007;16:1935–1953.
15. Nielsen HJ, Jakobsen KV, Christensen IJ, Brunner N for the Danish Study Group on early Detection of Colorectal Cancer. Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scan J Gastroenterol. 2011; 46:1283–1294.
16. Sanduleanu S, le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut. 2014. doi:10.1136/gutjnl-2014-307992.
17. Tao S, Hundt S, Haug U, Brenner H. Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease. Am J Gastroenterol. 2011;106:242–253.
18. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–1558. PMCID: 3749880.
19. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. PMCID: 4017867.
20. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci. 2005;102:16368–16373.
21. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massive parallel sequencing. Proc Natl Acad Sci. 2011;108:9350–9535.
22. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27:858–863.
23. Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008;3:e3759.
24. Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54:414–423.
25. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.
26. Hofsli E, Sjursen W, Prestvik WS, et al. Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013;108:1712–1719.
27. Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta. 2012;1820:1347–1353.
28. Patwa TH, Zhao J, Anderson MA, Simeone DM, Lubman DM. Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multi-lectin fluorescence detection. Anal Chem. 2006;78:6411–6421.
29. Yue T, Maupin KA, Fallon B, et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 2011;6:e29180. PMCID: 3248411.
30. Zhao J, Patwa TH, Qiu W, et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. Journal of proteome research. 2007;6:1864–1874.
31. Zhao J, Qiu W, Simeone DM, Lubman DM. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res. 2007;6:1126–1138.
32. Qiu Y, Patwa TH, Xu L, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res. 2008;7:1693–1703.
33. Rho JH, Mead JR, Wright WS, et al. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics. 2014;96:291–299.
34. Bresalier RS, Byrd JC, Tessler D, et al. A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology. 2004;127:741–748.
35. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma Insulin-like growth factor and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000;9:345–349.
36. Giovannucci E, Pollak M, Platz EA, et al. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses’ Health Study. Growth Horm IGF Res. 2000;10:S30–S301.
37. Palmquist R, Stattin P, Rinaldi S, et al. Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer. 2003;107:89–93.
38. Cruz-Correa M, Cui H, Giardiello FM, et al. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology. 2004;126:964–970.
39. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002;62:6442–6446.
40. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753–1755.
41. Woodson K, Flood A, Green L, et al. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst. 2004;96:407–410.
42. Narai S, Watanabe M, Hasegawa H, et al. Significance of Transforming growth factor beta 1 as a new tumor marker for colorectal cancer. Int J Cancer. 2002;97:508–511.
43. Broll R, Erdmann H, Duchrow M, et al. Vascular endothelial growth factor (VEGF)—a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol. 2001;27:37–42.
44. Takeda A, Shimada H, Imaseki H, et al. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep. 2000;7:333–338.
45. Feldman AL, Alexander HR Jr, Bartlett DL, et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol. 2001;8:741–745.
46. Peeters CF, Thomas CM, Sweep FC, Span PN, Wobbes T, Ruers TM. Elevated serum endothelin-1 levels in patients with colorectal cancer; relevance for prognosis. Int J Biol Markers. 2000;15:288–293.
47. Holten-Anderson MN, Christensen IJ, Nielsen HJ, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res. 2002;8:156–164.
48. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 2001;37:2392–2397.
49. Ladd JJ, Busald T, Johnson MM, et al. Increased plasma levels of the APC-interacting protein MAPRE-1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prv Res. 2012;5:655–664.
50. Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 2002;62:4041–4047.
51. Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets. 2007;11:235–244.
52. Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics. 2003;3:2108–2115.
53. Zaenker P, Ziman MR. Serologic autoantibodies as diagnostic cancer biomarkers—a review. Cancer Epidemiol Biomarkers Prev. 2013;22:2161–2181.
54. Reipert BM, Tanneberger S, Pannetta A, et al. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol Immunother. 2005;54:1038–1042.
55. He Y, Wu Y, Mou Z, et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl. 2007;1:336–342.
56. Chen Y, Lin P, Qiu S, et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol. 2007;30:1137–1144.
57. Liu W, Wang P, Li Z, et al. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol. 2009;69:57–63.
58. Lim SH, Becker TM, Chua W, Ng WL, de Souza P, Spring KJ. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol. 2014;67:848–853.
59. Zhang Z, Nagrath S. Microfluidics and cancer: are we there yet? Biomed Microdevices. 2013;15:595–609. PMCID: 4017600.
60. Murlidhar V, Zeinali M, Grabauskiene S, et al. A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small. 2014;10:4895–4904.
61. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification and prediction: Standards for study design. J Natl cancer Instit. 2008;100:1432–1438.
62. Surinova S, Sciess R, Huttenhein R, Ceciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J Proteome Res. 2011;10:5–16.
63. Toth K, Sipos F, Kalmar A, et al. Detection of methylated Sept9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLOS One. 2012;7:e46000.
64. Ladabaum U, Allen J, Wandell M, Ramsey S. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated Septin 9 DNA versus current strategies. Cancer Epidemiol Biomarkers Prev. 2013;22:1567–1576.
65. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other vesicles. Annu Rev Cell Biol. 2014;30:255–289.
66. Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8:113–117.